EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access

Effectiveness of Pneumococcal Conjugate Vaccination Against Virus-Associated Lower Respiratory Tract Infection Among Adults: A Case-Control Study

Joseph A Lewnard, Katia J Bruxvoort, Vennis X Hong, Lindsay R Grant, Luis Jódar, Alejandro Cané, Bradford D Gessner, Sara Y Tartof

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiac098 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Joseph A Lewnard und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology, School of Public Health, University of California, Berkeley, California, USA. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Pneumonia, Viruses, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interactions of Streptococcus pneumoniae with viruses feature in the pathogenesis of numerous respiratory illnesses.

Methods

We undertook a case-control study among adults at Kaiser Permanente Southern California between 2015 and 2019. Case patients had diagnoses of lower respiratory tract infection (LRTI; including pneumonia or nonpneumonia LRTI diagnoses), with viral infections detected by multiplex polymerase chain reaction testing. Controls without LRTI diagnoses were matched to case patients by demographic and clinical attributes. We measured vaccine effectiveness (VE) for 13-valent (PCV13) against virus-associated LRTI by determining the adjusted odds ratio for PCV13 receipt, comparing case patients and controls.

Results

Primary analyses included 13 856 case patients with virus-associated LRTI and 227 887 matched controls. Receipt of PCV13 was associated with a VE of 24.9% (95% confidence interval, 18.4%–30.9%) against virus-associated pneumonia and 21.5% (10.9%–30.9%) against other (nonpneumonia) virus-associated LRTIs. We estimated VEs of 26.8% (95% confidence interval, 19.9%–33.1%) and 18.6% (9.3%–27.0%) against all virus-associated LRTI episodes diagnosed in inpatient and outpatient settings, respectively. We identified statistically significant protection against LRTI episodes associated with influenza A and B viruses, endemic human coronaviruses, parainfluenza viruses, human metapneumovirus, and enteroviruses but not respiratory syncytial virus or adenoviruses.

Conclusions

Among adults, PCV13 conferred moderate protection against virus-associated LRTI. The impacts of pneumococcal conjugate vaccines may be mediated, in part, by effects on polymicrobial interactions between pneumococci and respiratory viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Tract InfectionsPneumoniaVirusesRespiratory Syncytial Virus, HumanPneumococcal InfectionsPneumonia, PneumococcalHumansAdultCase-Control StudiesStreptococcus pneumoniaeVaccinationVaccines, ConjugatePneumococcal Vaccines

Stichwörter der Autor:innen

human metapneumovirusinfluenzaparainfluenza viruspneumococcal conjugate vaccinepneumoniarespiratory syncytial virus

Substanzen

Vaccines, ConjugatePneumococcal Vaccines

Autor:innen und Institutionen

  • Division of Epidemiology, School of Public Health, University of California, Berkeley, California, USA.
  • Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, California, USA.
  • Center for Computational Biology, College of Engineering, University of California, Berkeley, California, USA.
  • Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Pfizer Vaccines, Collegeville, Pennsylvania, USA.

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • Pfizer
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Lewnard, J. A., Bruxvoort, K. J., Hong, V. X., Grant, L. R., Jódar, L., Cané, A., Gessner, B. D., & Tartof, S. Y. (2023). Effectiveness of Pneumococcal Conjugate Vaccination Against Virus-Associated Lower Respiratory Tract Infection Among Adults: A Case-Control Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiac098

Vancouver

Lewnard JA, Bruxvoort KJ, Hong VX, Grant LR, Jódar L, Cané A, et al. Effectiveness of Pneumococcal Conjugate Vaccination Against Virus-Associated Lower Respiratory Tract Infection Among Adults: A Case-Control Study. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiac098

BibTeX
@article{Lewnard2023,
  author = {Lewnard, Joseph A and Bruxvoort, Katia J and Hong, Vennis X and Grant, Lindsay R and Jódar, Luis and Cané, Alejandro and Gessner, Bradford D and Tartof, Sara Y},
  title = {Effectiveness of Pneumococcal Conjugate Vaccination Against Virus-Associated Lower Respiratory Tract Infection Among Adults: A Case-Control Study},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiac098}
}
Kostenlos starten →